RxDoctor Payments DataLook up a doctor →

David Deatkine, MD

Internal Medicine · Birmingham, ALNPI 1336255850

Payments from drug & device makers

$8,004,909in general payments, 2019–2025

Across 1,385 payments — averaging $5779.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3.2M
  • Eli Lilly$1.7M
  • AbbVie$974K
  • Modernatx, Inc.$865K
  • Ipsen Innovation$359K
  • Pfizer$308K
  • plus $630K from 54 others
$41,068in research payments, 2019–2025

Across 4 payments — averaging $10,267 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$41K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK201$3,177,028
Eli Lilly15$1,691,115
AbbVie(2 entities)194$974,384
Modernatx, Inc.54$865,168
Ipsen Innovation477$358,512
Pfizer33$308,491
Astrazeneca UK Limited3$271,333
AstraZeneca13$77,471
Johnson & Johnson9$67,263
Janssen Research & Development, LLC16$63,073
Sanofi US Services Inc.9$38,921
Bayer7$25,604
Regeneron1$17,500
Merck5$16,785
Genentech, Inc.4$11,750
Ionis Pharmaceuticals, Inc.9$11,000
Novo Nordisk AS19$7,403
Myovant Sciences Inc.3$7,000
Kowa Research Institute, Inc.4$5,585
Madrigal Pharmaceuticals1$1,463
Lexicon Pharmaceuticals, Inc.1$1,000
Dr.reddy's Laboratories,inc.1$864
Lilly USA, LLC41$812
Boehringer Ingelheim31$569
Esperion Therapeutics, Inc.23$555
Novo Nordisk23$457
Amgen24$424
Mannkind Corporation17$375
Corcept Therapeutics16$301
Amarin Pharma, Inc.14$295
Xeris Pharmaceuticals, Inc.16$286
Novartis15$265
Sanofi-aventis U.S. LLC12$252
CSL Behring5$198
BETA Bionics, Inc.3$189
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$161
Kowa Pharmaceuticals America, Inc.1$116
IBSA Pharma Inc.8$111
Therapeuticsmd, Inc.6$102
Tolmar, Inc.5$86
Abbott5$79
Insulet Corporation3$72
Takeda Pharmaceuticals U.S.A., Inc.3$50
Acella Pharmaceuticals, LLC3$45
Eisai Inc.3$39
Idorsia Pharmaceuticals US Inc2$31
Exact Sciences2$31
C2n Diagnostics, LLC1$28
Currax Pharmaceuticals LLC2$27
GC Biopharma USA, Inc.1$24
Rhythm Pharmaceuticals, Inc.1$24
Ultragenyx Pharmaceutical Inc.1$23
Dexcom, Inc.1$21
Nestle Healthcare Nutrition Inc.1$20
E.r. Squibb & Sons, L.L.C.1$19
Azurity Pharmaceuticals, Inc.1$19
Sequel Med Tech, LLC1$17
Vivus LLC1$17
Radius Health, Inc.1$17
Amneal Pharmaceuticals LLC1$15

How this compares

$8,004,909 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$97,858
Medicare patients
171
Services billed
5,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →